Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

Rigel said updated Phase 1b data for investigational R289 in relapsed or refractory lower-risk MDS, including preliminary dose-expansion efficacy and safety results, will be presented at ASH on Dec. 12, 2026; 64 patients were enrolled as of July 16. Fostamatinib findings include platelet counts ≥50 × 10³/µL in 81.6% of 38 ITP patients measured during months 7–12, versus 33.3% of 90 at baseline, and durable hemoglobin responses in >50% of 71 wAIHA patients through Week 104. These are conference disclosures and interim or retrospective findings; R289 remains investigational, and fostamatinib is investigational for wAIHA.

Analysis

RIGL’s value signal is concentrated in R289, but this is a catalyst setup, not evidence of a changed earnings trajectory. A randomized dose-expansion update could improve the program’s probability-adjusted value if transfusion benefit is durable and accompanied by tolerable safety; the small early-stage dataset and preliminary nature of the readout sharply limit what can be inferred about registrational success. Lower-risk MDS has established treatment alternatives, including luspatercept and imetelstat, so a signal must be differentiated on patient segment, durability, and transfusion burden—not just response counts.

Fostamatinib adds less incremental upside here: retrospective combination data and selected long-term follow-up are vulnerable to confounding and attrition, while wAIHA remains investigational. These findings may support clinician interest, but do not establish a near-term revenue step-up. The company’s promotional framing should be discounted until denominators, follow-up, discontinuations, and comparator context are available.

Near term, the December 12 presentation creates event volatility; a positive efficacy signal could lift pipeline optionality, while weak or ambiguous dose-expansion results risk giving back any catalyst premium. Over 6–18 months, the key question is whether R289 supports a larger, adequately powered study and ultimately a feasible regulatory path. No direct competitor trade is justified on this announcement alone. The thesis is falsified by limited or non-durable transfusion improvement, meaningful toxicity, or failure to advance the program. Cash runway and current valuation are also necessary before sizing any position.

Key Decisions for Investors

• Do not chase RIGL on the announcement alone. Treat it as a watchlist catalyst into ASH; the release contains no new efficacy result sufficient to underwrite a directional position.
• Review the full abstract and December 12 presentation before adding exposure. Require dose-expansion denominators, response duration, transfusion-independence or reduction rates, baseline burden, discontinuations, and safety by dose.
• If the readout is clearly differentiated and tolerable, consider a small, staged RIGL position only after checking valuation, cash runway, and event-day liquidity. Exit or avoid adding if efficacy is weak or transient, toxicity compromises dosing, or the study does not advance.
• Do not capitalize the fostamatinib posters as a material near-term sales catalyst without evidence of controlled benefit, commercial uptake, or a regulatory pathway for investigational settings; monitor whether follow-up and real-world data withstand selection-bias concerns.